Ambien CR Approval Includes Sleep Maintenance, Long-Term Use
Executive Summary
The approval of Sanofi-Aventis' Ambien CR (zolpidem extended-release) includes claims for sleep maintenance and long-term use that will allow the insomnia medication to compete against newer agents
You may also be interested in...
Ambien CR Generics Need Extra Bioequivalence Tests, Sanofi Argues To FDA
Sanofi-Aventis is requesting that FDA require additional bioequivalence tests for generic versions of its insomnia product Ambien CR (zolpidem extended-release)
Ambien CR Generics Need Extra Bioequivalence Tests, Sanofi Argues To FDA
Sanofi-Aventis is requesting that FDA require additional bioequivalence tests for generic versions of its insomnia product Ambien CR (zolpidem extended-release)
Ambien Class Action Suit May Serve As Wake-Up Call For Competitors
A civil class action lawsuit in Manhattan federal court alleging that Sanofi-Aventis failed to adequately warn patients of the risk of sleep walking and sleep eating with Ambien (zolpidem) could open the door for other agents in the highly competitive sleep category